AI Model Differentiates BCC vs cSCC Subtypes

• by Kathryn Wighton

• March 23, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

• by Kathryn Wighton

• July 2, 2026

• 3 min

Nodular Fasciitis May Mimic Sarcoma

Molecular testing may help avoid overtreatment when benign soft-tissue tumors present with atypical clinical or histologic features.

• by Andrea Surnit

• May 11, 2026

• 4 min

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min